Table 1 Patient characteristics, risk factors and treatment for hyperkalaemia
Patient variables | Total patients |
|---|---|
Overall cohort (n) | 8775 |
Age (years), mean (SD) | 64.7 (17.2) |
Sex (n, %) | |
Female | 3442 (39.2) |
Male | 5333 (60.8) |
Indigenous status (n, %) | |
Aboriginal and/or Torres Strait Islander | 1388 (15.8) |
Non-Indigenous | 7387 (84.2) |
Serum potassium level (mmoL/L), (n, %) | |
5.1–5.9 (Mild) | 6877 (78.4) |
6.0-6.4 (Moderate) | 996 (11.4) |
6.5 and above (Severe) | 902 (10.3) |
eGFR, mean (SD) | 63.8 (24.4) |
Comorbidities predisposing to hyperkalaemia (n, %) | |
Diabetes mellitus | 2918 (33.3) |
Hypoaldosteronism | 1 (0) |
Congestive heart failure | 489 (5.6) |
Cirrhosis | 167 (1.9) |
Medications predisposing to hyperkalaemia (n, %) | |
beta-blocker | 2579 (29.4) |
ACE-i/ARB | 3026 (34.5) |
Spironolactone | 804 (9.2) |
Trimethoprim | 199 (2.3) |
NSAIDS | 2844 (3.2) |
Digoxin | 428 (4.9) |
Potassium supplements | 1525 (7.4) |
Treatment for hyperkalaemia (n, %) | |
IV Calcium gluconate | 218 (2.5) |
PO Resonium | 1017 (11.6) |
IV Actrapid | 460 (5.2) |
IV Novorapid | 1227 (14.0) |
Inhaled salbutamol | 1474 (16.8) |
IV Sodium bicarbonate | 458 (5.2) |
Haemodialysis | 101 (1.2) |